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Abstract
Objective: This study was aimed to investigate the short- and long-term outcomes of percutaneous coronary
intervention (PCI) between single bare metal stent (BMS) and single drug eluting stent (DES) in nondiabetic
patients with a simple de novo lesion in the middle and large vessel.
Methods: Two hundred and thirty-five consecutive patients with a simple de novo lesion in the middle and large
vessel were treated with BMS or DES in our hospital from Apr. 2004 to Dec. 2004.
The inclusion criteria: a simple de novo lesion in the middle and large vessel, stent diameter ≥ 3.0 mm, stent length
≤ 18 mm, the exclusion criteria: diabetes mellitus, left main trunk disease and left ventricular ejection fraction ≤
30%. Of them, there were 150 patients in BMS group and 85 patients in DES group, and the rates of lost to follow
up were 6.7% and 1.2% respectively.
Results: BMS group had lower hypercholesteremia rate (22.0% vs 38.8%) and higher proportion of TIMI grade
0 (12% vs 1.2%) than DES group (all P < 0.05), but both groups had similar stent length (16.16 ± 2.81 mm vs 16.06
± 2.46 mm) and stent diameter (3.85 ± 3.07 mm vs 3.19 ± 0.24 mm) after procedure, in-segment restenosis rate
(0% vs 1.2%) and target lesion revascularization (TLR, 2.0% vs 2.4%) at 6-month follow-up (all P > 0.05). No
difference was found in TLR (1.3% vs 1.2%, P = 1.00) and recurrent myocardial infarction (Re-MI) (0% vs 1.2%, P
= 0.36), cardiac death (0.7% vs 1.2%, P = 1.00) between 1- and 3-year. So were TLR (6.0% vs 5.9%, P = 0.97), Re-
MI (0% vs 2.4%, P = 0.06), cardiac death (2.0% vs 3.5%, P = 0.48) and major adverse cardiac events (MACE, 8.7%
vs 10.6%, P = 0.63), cardiac death-free cumulative survival (98.7% vs 97.7%, P = 0.56), TLR-free cumulative survival
(94.0% vs 94.1%, P = 0.98) and Re-MI-free cumulative survival (100% vs 97.7%, P = 0.06) at 3-year follow-up.
Conclusion: The single BMS has similar efficacy and safety to single DES in nondiabetic patients with a simple de
novo lesion in the middle and large vessel at short- and long-term follow-up.
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Background
Drug eluting stent (DES) has dramatically reduced resten-
osis risks compared with bare metal stent (BMS) and con-
ventional balloon angioplasty [1-3]. Angiographic
analysis found that the majority of DES restenosis were
focal, localized, and bordered by segments with no angio-
graphic evidence of neointima, while BMS restenosis
tended to be diffuse or proliferative [4,5]. Thereby, DES
has revolutionized revascularization therapy and is rap-
idly becoming the standard for percutaneous coronary
intervention (PCI).
Although the incidence of late stent thrombosis is very
low, DES may increase the risk for late events, especially
associated with discontinuation of dual anti-platelet ther-
apy [6,7]. Considering that the patients are difficult in
anti-platelet compliance and more drug cost, we have to
ask whether all lesions need DES and what specific lesion
types are independent of DES therapy. Factors known to
increase the risks of in-stent restenosis include smaller
vessel diameter, prior restenosis, length of stented vessel,
and diabetes mellitus [8,9]. However, few of study
reported that a simple de novo lesion, for example, lesion
type A/B1[10,11] in the middle and large vessel was
treated with single BMS vs single DES at short- and long-
term follow-up.
Thus we investigated the efficacy and safety of single BMS
vs. single DES in nondiabetic patients with a simple de
novo lesion in the middle and large vessel at 6-month, 1-
year and 3-year follow-up in real world.
Methods
Study population
Demographic and procedural data were retrieved from a
dedicated PCI database between Apr 2004 to Dec 2004 at
Fu Wai hospital. Only a simple de novo lesion in single
middle and large vessel, stent diameter ≥ 3.0 mm, stent
length ≤ 18 mm were included. The unprotected left main
disease ≥ 50% stenosis, left ventricular ejection fraction ≤
30% and diabetic patients including definite diabetic
patients, newly diagnosed patients and diet controlled
patients were the major exclusion criteria. Finally, there
were 150 patients in BMS group and 85 patients in DES
group.
Procedures and relevant medications
All patients were pretreated with aspirin and either ticlo-
pidine or clopidogrel. A 300 mg loading dose of clopidog-
rel was administered before the procedure if patients were
not pretreated. During the procedure, a bolus dose of
unfractionated heparin (100 U/kg) was administered after
femoral or radial artery sheath insertion, with repeat bolus
given as needed to maintain activated cloting time
between 250 to 300 seconds. The administration of glyc-
oprotein IIb/IIIa inhibitors Tirofiban was left to the oper-
ator's discretion. The operators were free to use the BMS or
DES that they considered best. BMS included Coroflex
Delta, Driver, Express 2, micro-Driver, Multi-Link Mini
Vision, Multi-Link Vision, Multi-Link Zeta, Mustang and
Tecnic Carbostent, DES included Cypher, Cypher Select,
Firebird and Taxus Express 2.
All patients kept on aspirin therapy (300 mg/day for 3
months and 100 mg/day in lifelong time). Ticlopidine
(500 mg/day) or Clopidogrel (75 mg/day) was adminis-
tered for 6 to 12 months after DES implantation or for 3
months in BMS group.
Clinical definitions and follow-up
The clinical data were reviewed to obtain from a compu-
terized database by specialized personnel at the cardiovas-
cular interventional center in Fu Wai hospital. Risk factors
for coronary artery disease that were tabulated included
diabetes mellitus (only if treated medically), hypertension
(only if treated medically), and hyperlipidemia (only if
treated medically or if serum cholesterol was 240 mg/dl),
but in this study we excluded diabetic patients. The diag-
nosis of acute myocardial infarction (AMI) during hospi-
talization and follow-up was based on the presence of
new Q wave on electrocardiogram and/or elevation of cre-
atine kinase MB to at least three times the upper limit of
the normal range [12]. Simpsons method was used for
LVEF measurement by the blind to two observers.
Quantitative coronary angiography analysis was made
using a validated, edge detection system (MED CON QCA
software). Lesion length was defined as the distance from
the proximal to the distal shoulder of the lesion. The
degree of stenosis before and after angioplasty was meas-
ured after intracoronary injection of nitrates in the view
showing the most severe stenosis, and expressed as the
minimum lumen diameter and the linear percent lumen
diameter reduction, using the average diameter of the
nearest proximal and distal normal segments as the refer-
ence. In-segment restenosis was defined as diameter sten-
osis ≥ 50% within a previously stented segment (5 mm
proximal and distal to stent) using follow-up angiograms.
A blood flow rate of grade 1 or higher according to the
classification of the Thrombolysis in Myocardial Infarc-
tion (TIMI) trial.
Stent thrombosis was defined as occlusion of either vessel
or thrombus within or adjacent to a previously success-
fully stented vessel from angiographic evidence or, in the
absence of angiographic confirmation, either AMI in the
distribution of the treated vessel or death not clearly
attributable to other causes [13]. In-stent thrombosis was
categorized according to the timing of the event into:
acute thrombosis (within 24 hours after the procedure),Journal of Translational Medicine 2008, 6:42 http://www.translational-medicine.com/content/6/1/42
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subacute thrombosis (from postprocedure 1 to 30 days),
late thrombosis (> 30 days and < 1 year) and very late
thrombosis (≥ 1 year). Target lesion revascularization
(TLR) was defined as any symptom driven coronary artery
bypass graft or repeat PCI for restenosis or closure of the
target lesion. MACE included recurrent myocardial infarc-
tion (Re-MI), cardiac death and TLR. Data for patients
who did not have MACE were censored either at 3 years or
at the last known time of follow-up. Data for patients who
died before 3-year follow-up were censored at the time of
death.
A patient's clinical status was assessed by outpatient inter-
view or telephone conversation. All patients were asked to
return for coronary angiography approximately six
months after the procedure, or earlier if angina symptoms
occurred. Telephone interviews or outpatient interview
were repeated at twelve months and three years after the
procedure. Relevant data were collected and entered into
a computerized database by specialized personnel at the
cardiovascular interventional center in Fu Wai hospital.
Statistical analysis
All statistical analyses were performed with SPSS for Win-
dows (version 10.0, Chicago). Continuous variables were
described as mean ± SD, and categorical variables were
reported as percentages or proportions. The comparisons
of continuous variables were performed with unpaired t-
tests (normal distribution) and nonparametric Mann-
Whitney U test (skew distribution). The analysis of cate-
gorical variables was performed with Fisher's exact test
and Chi-square test. Kaplan-Meier time-to-event estimates
was used for the primary events at 1-year and 3-year of fol-
low-up, which were compared with the log-rank test
between BMS group and DES group. All reported P values
were two-sided, and a P value < 0.05 was considered sta-
tistically significant.
Results
Baseline clinical characteristics were shown in table 1.
Compared to DES group, the patients in BMS group had
lower hypercholesteremia rate (22.0% vs 38.8%, P =
0.006), but age, gender, other risk factors for coronary
artery disease and left ventricular function were similar in
the two groups (all P > 0.05).
During procedure and in-hospital, BMS group had higher
proportion of TIMI grade 0 than DES group (12.0% vs
1.2%, P < 0.05), but other variable including calcified
lesion (%), lesion length (mm), stent diameter (mm),
percentage of lumen stenosis (%), balloon predilatation
(%), stent length (mm), post-dilatation (%), vessel dissec-
tion (%), postprocedural residual stenosis (%) and in-
hospital outcomes did not significantly differ (all P >
0.05) in table 2. Despite that BMS had higher acute
thrombosis rate than DES (3.3% vs 0%, P = 0.162), these
patients recovered reperfusion after thrombolysis and
intra-aortic balloon pump therapy, there were not in-hos-
pital TLR and death in BMS group.
Repeat coronary angiography at 6-month follow-up
showed similar acute and subacute thrombosis (%), late
thrombosis (%), in-segment restenosis (%), TLR (%) and
composite of cardiac death or Re-MI (%) in the two
groups (all P > 0.05) in table 3.
The rates of lost to follow up at 3-year follow-up were
6.7% and 1.2% between BMS and DES group. The both
groups had not significant differences in primary events
including TLR (1.3% vs 1.2%, P = 1.00) and recurrent
myocardial infarction (Re-MI) (0% vs 1.2%, P = 0.36) or
cardiac death (0.7% vs 1.2%, P = 1.00) between 1- and 3-
year, So were Re-MI (%), cardiac death (%), TLR (%) and
MACE (%) at 1- and 3-year follow-up (all P > 0.05) in
table 4.
The cumulative survival free of cardiac death in BMS
group vs DES group was 100% vs 100% (Log rank P =
1.000) at 1-year and 98.67% vs 97.65% (Log rank P =
0.559) at 3-year follow-up (Fig. 1). Similarly, TLR-free
cumulative survival between BMS group and DES group
was 95.33% vs 95.29% (Log rank P = 0.978) at 1-year and
Table 1: Baseline Clinical Characteristics
Characteristics BMS group
(N = 150 Pts)
DES group
(N = 85 Pts)
P value
Age (years) 56.66 ± 11.72 58.26 ± 11.14 0.307
Male (%) 80.7 78.8 0.734
Hypercholesteremia (%) 22.0 38.8 0.006
Hypertension (%) 50.7 60.0 0.168
Family history of CAD (%) 3.3 3.5 0.937
Smoking (%) 37.3 38.8 0.821
Unstable angina history (%) 72.0 75.3 0.198
Acute myocardial infarction (%) 34.7 23.5 0.075
LVEF (%) 63.24 ± 23.23 68.43 ± 17.06 0.108
Note: Pts, patients; CAD, coronary artery disease; LVEF, left ventricular ejection fraction.Journal of Translational Medicine 2008, 6:42 http://www.translational-medicine.com/content/6/1/42
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94.00% vs 94.12% (Log rank P = 0.984) at 3-year follow-
up (Fig. 2). Noticeably, there was a trend towards a
decrease of Re-MI-free cumulative survival in the DES
group compared with the BMS group at 1-year (98.82% vs
100%, Log rank P = 0.183) and 3-year follow-up (97.65%
vs 100%, Log rank P = 0.059) (Fig. 3).
Discussion
This is the first study to investigate efficacy and safety of
single BMS vs. single DES in nondiabetic patients with a
simple de novo lesion in the middle and large vessel at 3-
year follow-up in real world. The present study found that
both DES group and BMS group had similar acute and
subacute thrombosis (%), late thrombosis (%), in-seg-
ment restenosis (%), TLR (%), composite of cardiac death
or Re-MI (%) at 6-month follow-up, so were Re-MI (%),
cardiac death (%), TLR (%) and MACE (%) at 1- and 3-
year follow-up in the two groups, furthermore, nonsignif-
icant difference in the cardiac death-free and TLR-free
cumulative survival rates except that there was a trend
towards a decrease of Re-MI-free cumulative survival rate
in DES group compared with BMS group at 1- and 3-year
follow-up (all P > 0.05).
The previous study found that vessel diameter was an
established predictor of angiographic outcome after cath-
eter-based intervention, with a higher restenosis rate in
smaller vessels [14]. Thereby, at the time of these pilot
studies, sirolimus-eluting stents were only available in a
3.0 mm or 3.5 mm diameter, limiting treatment to rela-
tively large vessels, these sirolimus-eluting stents showed
0% restenosis at 4-month [15], 6-month [16], and 12-
month [17]. Later, a study demonstrated that the classic
inverse relationship between vessel diameter and resteno-
sis rate was seen in the BMS group but not in the
sirolimus-eluting stent group [18], and vessel sizes of 2.5
– 3.5 mm were allowed in the subsequent randomized
study with the sirolimus-coated Bx velocity balloon-
Table 2: Angiographic characteristics and in-hospital outcomes
Characteristics BMS group
(N = 150 Pts)
DES group
(N = 85 Pts)
P value
Calcified lesion (%) 0.282
None 79.9 70.6
Slightness 15.4 18.8
Moderation 3.4 8.2
Severity 1.3 2.4
Lesion length (mm) 12.60 ± 4.05 11.65 ± 3.09 0.062
Percentage of lumen stenosis (%) 87.82 ± 8.70 85.73 ± 8.48 0.075
TIMI grade 0.030
0 12.0 1.2
1 3.3 2.4
2 14.7 17.6
3 70.0 78.8
Balloon predilatation (%) 63.3 56.5 0.300
Stent length (mm) 16.16 ± 2.81 16.06 ± 2.46 0.782
Stent diameter (mm) 3.85 ± 3.07 3.19 ± 0.24 0.050
Post-dilatation (%) 15.4 25.6 0.060
Vessel dissection (%) 0 1.2 0.363
Acute thrombosis (%) 3.3 0 0.162
Postprocedural residual stenosis (%) 0.21 ± 1.15 0.29 ± 1.61 0.656
In-hospital TLR (%) 0 1.2 0.183
In-hospital cardiac death (%) 0 0 ......
Note: Pts, patients; TLR, target lesion revascularization.
Table 3: The procedural characteristics and 6-month outcomes
Characteristics BMS group
(N = 150 Pts)
DES group
(N = 85 Pts)
P value
Subacute thrombosis (%) 0 0 ......
Late thrombosis (%) 0 2.4 0.129
In-segment restenosis (%) 0 1.2 0.258
Composite of cardiac death or Re-MI (%) 0 1.2 0.362
TLR (%) 2.0 2.4 1.000
Note: Pts, patients; Re-MI, recurrent myocardial infarction; TLR, target lesion revascularization.Journal of Translational Medicine 2008, 6:42 http://www.translational-medicine.com/content/6/1/42
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expandable stent in the treatment of patients with de
novo native coronary artery lesions (RAVEL) trial, yet
lesions still had to be covered with one stent [19].
Currently, based on a lot of studies, people began to
believe that the restenosis at the site of stent implantation
seen in 15–60% of patients was dependent on various
confounding factors, such as the presence or absence of
diabetes mellitus, the size of the targeted coronary artery,
the length of the coronary lesion, and the degree of vessel
patency achieved by the intervention [20-25]. DES has
been shown to reduce the risk of restenosis compared
with BMS [1,19,25,26]. Despite that treatment of specific
lesions types, especially in stent restenosis and distal sten-
osis of left main coronary, as well as diabetic patients,
remains suboptimal with DES, whereas considering that
Table 4: Clinical outcomes at 1-year and 3-year follow-up between DES group and BMS group
Events 1-year follow-up 3-year follow-up Between 1-year and 
3-year follow-up
BMS group
(N = 150 Pts)
DES group
(N = 85 Pts)
PB M S  g r o u p
(N = 150 Pts)
DES group
(N = 85 Pts)
PB M S  g r o u p
(N = 150 Pts)
DES group 
(N = 85 Pts)
P
Re-MI (%) 0 1.2 0.36 0 2.4 0.06 0 1.2 0.36
Cardiac death (%) 1.3 2.4 0.62 2.0 3.5 0.48 0.7 1.2 1.00
TLR (%) 4.7 4.7 1.00 6.0 5.9 0.97 1.3 1.2 1.00
MACE (%) 6.0 7.1 0.75 8.7 10.6 0.63 2.7 3.5 0.71
Note: Pts, patients; Re-MI, recurrent myocardial infarction; TLR, target lesion revascularization; MACE, major adverse cardiac events.
The Cardiac death-free cumulative survival between BMS group and DES group at 1-year and 3-year followup Figure 1
The Cardiac death-free cumulative survival between BMS group and DES group at 1-year and 3-year followup.Journal of Translational Medicine 2008, 6:42 http://www.translational-medicine.com/content/6/1/42
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DES practice including complex interventions is safe and
associated with significant reductions in clinical driven
repeat revascularization rates [27]. Moreover, DES also
can effectively treat in-stent restenosis and saphenous vein
graft restenosis [28-30], thus it appears to be the advent of
transition from BMS to DES in routine PCI practice.
However, we do not disregard an important problem of
DES, that is, thrombosis. Especially subacute in-stent
thrombosis could occur more frequently with DES than
with BMS and a prolonged anti-platelet regimen is man-
datory [31]. In spite of the use of anti-platelet agents, stent
thrombosis occurs in approximately 1% of patients, with
an increased likelihood of occurrence in high-risk patients
or complex lesion subset of patients [32,33]. According to
the previous report, triple anti-platelet therapy (aspirin +
clopidogrel + cilostazol) seemed to be more effective in
preventing thrombotic complications after stenting than
dual anti-platelet agent [34], but latterly a case report
showed a patient with subacute stent thrombosis involv-
ing two different arteries simultaneously under the use of
triple anti-platelet regimen [31]. Therefore, the promises
of this potential panacea – DES, have been recently atten-
uated by the specter of late and very late stent thrombosis
because of anti-platelet discontinuation [35-38]. How-
ever, the large-scale clinical trials and pool analysis dem-
onstrated that the beneficial effect of DES on reducing the
need for new revascularization compared with BMS
extends to 4 years without evidence of a worse safety pro-
file including thrombosis [39-42].
In our study, the specific lesion was choiced in the nondi-
abetic patients, and both BMS group and DES group had
similar post-procedural outcomes including balloon pre-
dilatation (%), stent length (mm), stent diameter (mm),
post-dilatation (%), vessel dissection (%) and postproce-
dural residual stenosis (%), finally we found that the both
groups had similar acute and subacute thrombosis (%),
late thrombosis (%), in-segment restenosis (%), TLR(%),
composite of cardiac death or Re-MI (%) at 6-month fol-
TLR-free cumulative survival between BMS group and DES group at 1-year and 3-year follow-up Figure 2
TLR-free cumulative survival between BMS group and DES group at 1-year and 3-year follow-up.Journal of Translational Medicine 2008, 6:42 http://www.translational-medicine.com/content/6/1/42
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low-up and Re-MI (%), cardiac death (%), TLR (%) as well
as MACE (%) at 1- and 3-year follow-up, so were the car-
diac death-free and TLR-free cumulative survival rate,
however, there was a trend towards a decrease of Re-MI-
free cumulative survival rate in the DES group compared
with the BMS group at 1- and 3-year follow-up (all P >
0.05), we presumed that the Re-MI might be associated
with very late thrombosis. In view of less cost, short-term
anti-platelet regimen, less thrombosis incidence, similar
restenosis rate and TLR rate in BMS compared with DES,
suggesting that BMS may has similar efficacy and superior
safety compared with DES at 3-year follow up, thus the
nondiabetic patients with a simple de novo lesion in the
middle and large vessel seem to have other benefit from
BMS instead of DES in real world.
Limitation
Firstly, we investigated the non-diabetic patients with spe-
cific lesion in real world, the design of this trial was not
randomized controlled trial (RCT), thereby the patients in
BMS group had lower hypercholesteremia rate (22.0% vs
38.8%, P = 0.006) than DES group in baseline clinical
characteristics, thereafter it is necessary for the RCT trials'
investigation. Secondly, this is a small population and
single medical center of investigation, thus it needs the
large-scale trials to validate these findings. Thirdly, this
study did not present very late thrombosis data, though it
was few of incidence, the very late thrombosis should be
investigated in future trials.
Conclusion
The single BMS has similar efficacy and safety to single
DES in non-diabetic patients with a simple de novo lesion
in the middle and large vessel at short- and long-term fol-
low-up.
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